Berberine enhances cisplatin efficacy in ehrlich ascites carcinoma via modulation of apoptotic pathway and efferocytosis.

Maha M Salem, Safia M Dawod, Tarek M Mohamed, Wafaa M Ibrahim, Amira T Khattab

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maha M SalemBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31257, Egypt. maha_salem@science.tanta.edu.eg.ORCID 0000-0002-9108-6932

Safia M DawodBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31257, Egypt.

Tarek M MohamedBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31257, Egypt.

Wafaa M IbrahimMedical Biochemistry Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Amira T KhattabBiochemistry Department, Faculty of Science, Damanhour University, Damanhour, 22514, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Berberine, a bio-alkaloid from medicinal plants, shows therapeutic potential against various ailments, including cancer. This study evaluated berberine's effects on the PI3K/Akt pathway and efferocytosis in an adenocarcinoma model to reduce cisplatin chemotherapy side effects and Ehrlich ascites carcinoma (EAC) proliferation. Eighty Swiss albino mice were divided into eight groups: control, berberine, cisplatin, cisplatin & berberine, EAC, EAC & berberine, EAC & cisplatin, and EAC & cisplatin & berberine. Tumor response, weight change, cell count, survival analysis, biochemical analysis, molecular studies, and histopathological assessment were performed. Results showed berberine enhanced cisplatin's antitumor efficacy in EAC-bearing mice by reducing tumor volume and cell counts. Berberine ameliorated cisplatin's hepato-renal toxicity and downregulated Akt1, Axl, Mertk, and Gas6 gene expression. Histopathological analysis showed berberine's ability to recover cisplatin's lethal effects on liver tissue. In conclusion, berberine showed promising effects on the PI3K/Akt pathway and efferocytosis, reducing cisplatin's side effects and EAC proliferation.

Indexed as

Antineoplastic AgentsApoptosisBerberineCarcinoma, Ehrlich TumorCisplatinAnimalsCell ProliferationEfferocytosisLiverMaleMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic AgentsBerberineCisplatinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktApoptosisBerberineCisplatinEfferocytosisEhrlich Ascites CarcinomaPhagocytosisPI3K/Akt pathway

Identifiers

PMID42049890

DOI10.1038/s41598-026-49296-3

PMCPMC13125636

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.